{"prompt": "['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen, Inc.', 'PROTOCOL SUMMARY', 'Study Title', 'A phase 4, multi-center, randomized, double-blind, placebo-controlled study of the impact of', 'apremilast (CC-10004) on quality of life, efficacy, and safety in subjects with manifestations of', 'plaque psoriasis and impaired quality of life.', 'Indication', 'Psoriasis vulgaris is a chronic inflammatory immunologic disorder which manifests primarily in', 'the skin. It is characterized by sharply demarcated areas of affected skin which appear thickened,', 'red, and scaly. The scalp, elbows, knees, lower back, hands, and feet are commonly affected', 'sites. About 80% of affected patients complain of pruritus (Gottlieb, 1998). The psoriatic', 'appearance of the skin is initiated by an antigen presenting cell (APC) - T-cell interaction', 'leading to the release of multiple inflammatory cytokines (Nestle, 2009). In time, this leads to an', 'increased rate of epidermal proliferation with impaired differentiation of keratinocytes, resulting', 'in a thickened epidermis covered by a thickened, parakeratotic stratum corneum. Dermal', 'capillaries become tortuous and dilated, and there is infiltration of both epidermis and dermis', 'with imunologically active cells (Lowes, 2007).', 'According to a European consensus statement on the definition of treatment goals for patients', 'with plaque psoriasis, mild psoriasis is defined as body surface area (BSA) < 10% and Psoriasis', 'Area Severity Index (PASI) < 10 and Dermatology Life Quality Index (DLQI) 10. However,', 'patients with mild psoriasis, as indicated by the somatic scores, BSA and PASI, may present with', 'disease manifestations not adequately controlled by topical therapy alone which, in addition, may', 'lead to a significantly impaired quality of life. These manifestations can include the following:', 'involvement of visible areas, involvement of major parts of the scalp, involvement of genitals,', 'involvement of palms and/or soles, onycholysis or onychodystrophy of at least two fingernails,', 'pruritus leading to scratching, and presence of single recalcitrant plaques.', 'The presence of any of the previously mentioned manifestations alters the classification of mild', 'psoriasis to moderate to severe psoriasis in need of systemic therapy due to significantly', 'impaired quality of life (Mrowietz, 2011).', 'Objectives', 'Primary Objective', 'To assess the impact of apremilast 30 mg twice daily (BID), compared to placebo,', 'on Health-related Quality of Life (QOL) in subjects with manifestations of plaque', 'psoriasis and impaired quality of life at Week 16', 'Secondary Objectives', 'To assess the efficacy and safety of apremilast 30 mg BID, compared to placebo', 'in subjects with manifestations of plaque psoriasis and impaired quality of life at', 'Week 16', 'To assess the long-term effects of apremilast 30 mg BID, with respect to quality', 'of life, efficacy, and safety at Weeks 32 and 52', 'Confidential and Proprietary', '6', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen, Inc.', 'Study Design', 'The study will be conducted in compliance with International Council for Harmonisation (ICH)', 'Good Clinical Practices (GCPs). This is a Phase 4, multi-center, randomized, placebo-controlled,', 'double-blind study of the impact of apremilast on quality of life, efficacy, and safety in subjects', 'with manifestations of plaque psoriasis and impaired quality of life.', 'Approximately 255 subjects will be randomized 2 (apremilast): 1 (placebo) in approximately 6 to', '10 countries in Western Europe. Subjects will be block-randomized to each of the 5', 'manifestations of plaque psoriasis. If subjects present with multiple manifestations, they will be', 'allocated to the manifestation which is most severe, as determined by the subject. However, all', 'manifestations will be assessed for efficacy at each study visit.', 'After a 5-day titration with apremilast, subjects will receive apremilast 30 mg tablets', 'or matching placebo orally twice daily (BID) for 16 weeks. Subjects randomized to', 'the apremilast treatment group will receive apremilast 30 mg tablets orally twice daily', 'for 52 weeks.', 'Subjects randomized to the placebo treatment group will receive placebo tablets', '(identical in appearance to the apremilast 30 mg tablets) orally twice daily for 16', 'weeks. Beginning at Week 16 and after a 5-day titration with apremilast, subjects', 'initially randomized to placebo will be switched to receive apremilast 30 mg BID for', 'an additional 36 weeks (52 weeks total).', 'The study will consist of 4 phases:', 'Screening Phase - up to 5 weeks (35 days)', 'Double-blind Placebo-controlled Phase - Weeks 0 to 16', 'Subjects will receive treatment with either:', '- Apremilast 30 mg tablets orally BID, or', '- Matched placebo tablets orally BID', 'Apremilast Extension Phase - Weeks 16 through 52', '- All subjects will be switched to (or continue with) apremilast 30 mg BID at', 'Week 16 (after a 5-day titration for subjects initially randomized to placebo). All', 'subjects will maintain this dosing to Week 52.', 'Post-treatment Observational Follow-up Phase', '-', '4-week post-treatment observational follow-up for all subjects who complete the', '52-week study treatment or discontinue from the study treatment early', 'Study Population', 'Adult subjects > 18 years of age with manifestations of plaque psoriasis and impaired quality of', 'life.', 'Length of Study', 'The study is designed as a 52-week study, with a 4-week post-treatment observational follow-up.', 'Visits will be scheduled at screening (no more than 5 weeks prior to randomization), Week 0', 'Confidential and Proprietary', '7', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen, Inc.', '(baseline/randomization), Weeks 2, 4, 16, 20, 32, 44, and 52. A post-treatment observational', 'follow-up will be conducted by telephone at Week 56 or 4 weeks after subject discontinues from', 'the study treatment.', 'The End of Trial is defined as either the date of the last visit of the last subject to complete the', 'post-treatment follow-up, or the date of receipt of the last data point from the last subject that is', 'required for primary, secondary, and/or exploratory analysis, as pre-specified in the protocol,', 'whichever is the later date.', 'Study Treatments', 'Subjects will be dispensed blister cards with 10, 20, and 30 mg apremilast tablets, or identically', 'appearing placebo, for the dose titration, at the baseline visit (Week 0). The treatment schema for', 'dose titration at Baseline is shown in Appendix P.', 'Starting at Week 16, all subjects will be switched to, or will continue with, apremilast. Subjects', 'originally randomized to placebo at Week 0 will be switched to apremilast at Week 16. Dose', 'titration blister cards will be used for subjects switching from placebo to apremilast; blister cards', 'with dummy titration (dosing at 30 mg BID directly) will be used for subjects originally', 'randomized to apremilast. Beginning with the Week 20 visit, all subjects will receive open label', 'high-density polyethylene (HDPE) bottles of investigational product (IP) tablets. All subjects', 'will maintain this dosing through Week 52.', 'Apremilast tablets will be taken orally twice daily, approximately 12 hours apart, through the last', 'treatment visit.', 'Overview of Key Efficacy Assessments', 'Primary Efficacy Endpoint', 'The primary endpoint will be the proportion of subjects who achieve a > 4-point reduction from', 'baseline in the DLQI in subjects receiving apremilast compared to placebo at Week 16.', 'Secondary Efficacy Enppoints', 'Dermatology Life Quality Index (DLQI)', 'Itch Numeric Rating Scale (NRS)', 'Skin Discomfort/Pain Visual Analog Scale (VAS)', 'Body Surface Area (BSA)', 'Psoriasis Area and Severity Index (PASI)', 'Patient Benefit Index (PBI)', 'European Quality of Life 5-Dimension Questionnaire (EQ-5D)', 'The Work Productivity and Activity Impairment Questionnaire: Psoriasis (WPAI:', 'PSO)', 'Overview of Key Safety Assessments', 'Safety assessments will include:', 'Adverse events (AE)', 'Confidential and Proprietary', '8', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']", "completion": ""}